Projects per year
Personal profile
Personal profile
After graduation from medical school in 2008, Dr. Faridar gained extensive experiences of running translational research projects as a research fellow and post-doctoral scholar in prestigious institutes in Europe and the USA. His effort as a post-doctoral research scholar in neuroscience department at UCSF culminated in developing a new blood biomarker in Autism. In 2013, Dr. Faridar joined the Neurology Residency Program at the Houston Methodist Neurological Institute. During his residency and subsequent fellowship, he worked on Alzheimer’s disease under the mentorship of Drs. Joseph Masdeu and Stanley H. Appel. He is particularly interested in evaluating the inflammation and potential immunotherapy in Alzheimer disease. Dr. Faridar is a recipient of the prestigious “BrightFocus Alzheimer Disease Research Fellowship” and “Alzheimer’s Association Part-The-Cloud” Awards and has published over 26 peer-reviewed papers and book chapters.
Research interests
Inflammation is a significant component of neurodegenerative disorder including Alzheimer’s disease. From his research during residency through to his current role as assistant professor of neurology, Dr. Faridar has assessed inflammatory signaling cascades in neurodegenerative process. One of his major contributions in this area is studying the status of the adaptive immune system in Alzheimer’s disease and its role as a potential therapeutic target. Regulatory T cells (Tregs) play a neuroprotective role by suppressing microglia/macrophage-mediated inflammation and modulating adaptive immune reactions. Dr. Faridar and his team observed that Tregs of Alzheimer’s disease patients lose their ability to suppress inflammation. However, these dysfunctional Tregs might be a restorable therapeutic target. Based on this finding, Dr. Faridar and his team are conducting a phase I/IIa study to assess the safety and potential efficacy of an in vivo Treg expansion strategy in Alzheimer’s disease patients with promising preliminary findings.
External positions
Assistant Professor of Neurology, Weill Cornell Medical College
Dec 1 2020 → …
Research Area Keywords
- Neurosciences
- Clinical Care
- Clinical Translation & Trials
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disorders
9/30/24 → 8/31/25
Project: Federal Funding Agencies
-
A Phase I Clinical Trial, Using Interleukin-2 (IL-2) and Abatacept in Patients with Frontotemporal Disorders
Faridar, A., Appel, S. H., Masdeu, J. C. & Pascual, B.
6/10/24 → …
Project: Clinical Trial
-
Biomarker in Aging-Related Disorders (BARD)
Toledo, J. B., Faridar, A., Masdeu, J. C. & Pascual, B.
4/23/24 → …
Project: Clinical Trial
-
Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy
1/1/23 → 12/31/25
Project: Federal Funding Agencies
-
Imaging for Precision Medicine in Alzheimer's Disease and Related Disorders
Masdeu, J. C., Faridar, A., Karmonik, C., Nakawah, M. O., Pascual, B. & Roman, G. C.
5/25/22 → …
Project: Clinical Trial
-
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis
Thonhoff, J. R., Beers, D. R., Zhao, W., Faridar, A., Thome, A., Wen, S., Zhang, A., Wang, J. & Appel, S. H., 2024, In: Frontiers in Neurology. 15, p. 1415106 1415106.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis
Thonhoff, J. R., Beers, D., Zhao, W., Faridar, A., Thome, A. D., Wen, S., Zhang, A., Wang, J. & Appel, S. H., Jun 2024, In: Frontiers in Neurology. 15, p. 1415106 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease
Appleton, J., Finn, Q., Zanotti-Fregonara, P., Yu, M., Faridar, A., Nakawah, M. O., Zarate, C., Carrillo, M., Dickerson, B. C., Rabinovici, G., Apostolova, L. G., Masdeu, J. C. & Pascual, B., Jul 16 2024, (E-pub ahead of print) In: Brain.Research output: Contribution to journal › Article › peer-review
-
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
Faridar, A., Eid, A. M., Thome, A. D., Zhao, W., Beers, D. R., Pascual, M. B., Nakawah, M. O., Roman, G. C., Davis, C. S., Grundman, M., Masdeu, J. C. & Appel, S. H., Nov 16 2023, In: Translational Neurodegeneration. 12, 1, p. 54 54.Research output: Contribution to journal › Letter › peer-review
Open Access5 Scopus citations -
Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation
Thome, A. D., Thonhoff, J. R., Zhao, W., Faridar, A., Wang, J., Beers, D. R. & Appel, S. H., Jun 22 2022, In: Frontiers in immunology. 13, p. 875825 875825.Research output: Contribution to journal › Article › peer-review
Open Access14 Scopus citations